Statements (66)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Antihero
|
| gptkbp:approves |
gptkb:FDA
1953 |
| gptkbp:available_on |
generic
|
| gptkbp:brand |
gptkb:Dilantin
|
| gptkbp:category |
gptkb:D
|
| gptkbp:chemical_formula |
C15 H12 N2 O2
|
| gptkbp:condition |
status epilepticus
focal seizures partial seizures seizure disorder tonic-clonic seizures |
| gptkbp:contraindication |
hypersensitivity to phenytoin
|
| gptkbp:dosage_form |
gptkb:tablet
gptkb:capsule 100 mg suspension 400 mg 300 mg |
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
Dilantin
|
| gptkbp:ingredients |
gptkb:phenytoin
|
| gptkbp:interacts_with |
gptkb:beer
gptkb:warfarin oral contraceptives |
| gptkbp:is_monitored_by |
liver function tests
complete blood count serum phenytoin levels |
| gptkbp:lifespan |
22 hours
|
| gptkbp:manufacturer |
gptkb:Pfizer
|
| gptkbp:metabolism |
liver
|
| gptkbp:route_of_administration |
oral
intravenous |
| gptkbp:side_effect |
gptkb:anemia
dizziness fatigue nausea sleep disturbances liver toxicity ataxia drowsiness arrhythmias headaches skin rash thrombocytopenia osteoporosis nystagmus cognitive impairment hypotension vitamin D deficiency neuropathy mood changes gum overgrowth hyperglycemia leukopenia hypomagnesemia hypocalcemia hirsutism coarsening of facial features |
| gptkbp:symptoms |
seizures
increased seizure frequency |
| gptkbp:used_for |
treating epilepsy
controlling seizures |
| gptkbp:weight |
252.26 g/mol
|
| gptkbp:bfsParent |
gptkb:phenytoin
|
| gptkbp:bfsLayer |
6
|